(RTTNews) - Medical devices companySt. Jude Medical, Inc. (STJ: News ) Tuesday said subset data results for the Angio-Seal Evolution Vascular Closure Device Registry reaffirmed the excellent sealing performance of the Angio-Seal Evolution vascular closure device in patients undergoing routine diagnostic and interventional cardiac catheterization procedures.
The Angio-Seal Evolution device is designed to enable physicians to quickly and effectively seal femoral artery punctures made during minimally invasive catheter-based procedures.
The company noted that the results validated the exceptional performance of the device after being successfully deployed in 99.7% of procedures and with hemostasis achieved in 97.8% of these procedures by the device.
This new subset analysis strengthens those findings by demonstrating no significant difference in deployment success or hemostasis for patients with challenging conditions that might negatively impact device performance, such as obesity and scar tissue at the vascular access site, the company added.
No comments:
Post a Comment